Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

Australian biotech giant CSL Ltd CSL.AX' reported on Tuesday a net profit rise of 13% in the first half, bolstered by strong demand and increased plasma collection at its Behring unit. The company, ...

On Thursday, Goldman Sachs began coverage on shares of CSL Ltd (OTC:CSLLY). (CSL:AU) (OTC: CMXHF) with a Buy rating and a price target set at AUD325.40. The new target indicates a potential 17% upside ...

CSL Limited achieved a +3% earnings beat for 1H FY 2024, and the company's full-year FY 2024 financial guidance was left unchanged. But CSL Limited's CSL112 trial results were unfavorable, which ...

Should you be buying the dip? Let's find out. The post Why did CSL shares crash 39% in 2025? appeared first on The Motley Fool Australia.

Ladies and gentlemen, good morning, and welcome to CSL's first half results call for fiscal 2024. It's Mark Dehring speaking, and I'm pleased to be joined by several of CSL's leadership team. With me ...